SelectQuote (SLQT) Proxy Filing summary
Event summary combining transcript, slides, and related documents.
Proxy Filing summary
1 Dec, 2025Executive summary
The 2025 Annual Meeting will be held virtually on November 11, 2025, with voting on director elections, auditor ratification, and executive compensation.
Only shareholders of record as of September 23, 2025, are eligible to vote; a majority of shares constitutes a quorum.
The Board recommends voting FOR all proposals, including the election of two Class III directors, ratification of Deloitte & Touche LLP, and approval of executive compensation.
Voting can be done online, by phone, mail, or during the meeting; votes can be changed prior to the meeting.
Voting matters and shareholder proposals
Proposal 1: Elect two Class III directors (Denise L. Devine and Donald L. Hawks III) for terms expiring in 2028.
Proposal 2: Ratify Deloitte & Touche LLP as independent auditor for fiscal year ending June 30, 2026.
Proposal 3: Approve, on a non-binding basis, the compensation of named executive officers (say-on-pay).
Board recommends FOR all proposals; voting results will be disclosed in a Form 8-K.
Board of directors and corporate governance
Board consists of eight directors, with a majority qualifying as independent under NYSE standards.
Board is classified into three staggered classes; separation of CEO and Chairman roles for effective oversight.
Four standing committees: Audit, Compensation and Talent Development, Nominating and Corporate Governance, and Healthcare Oversight.
Regular executive sessions held without management; robust stockholder engagement and communication processes.
Directors are subject to stock ownership guidelines and a code of business conduct and ethics.
Latest events from SelectQuote
- Revenue up 12% to $537.1M, net income $69.3M, and guidance cut by $40M amid external headwinds.SLQT
Q2 20265 Feb 2026 - FY2024 revenue and EBITDA beat guidance; 2025 growth limited by capital, but outlook strong.SLQT
Q4 202420 Jan 2026 - Revenue up 26% with strong pharmacy growth; $100M securitization boosts capital flexibility.SLQT
Q1 202517 Jan 2026 - Q2 revenue up 19% to $481.1M, net income $53.2M, $350M equity investment secured.SLQT
Q2 202523 Dec 2025 - All proposals passed, including director elections and auditor ratification, with no shareholder questions.SLQT
AGM 202516 Dec 2025 - Board recommends approval of all proposals, highlighting governance and pay-for-performance.SLQT
Proxy Filing1 Dec 2025 - Virtual annual meeting to vote on directors, auditor, and executive pay, with board support.SLQT
Proxy Filing1 Dec 2025 - Annual meeting to vote on directors, auditor, and executive pay, with board support for all.SLQT
Proxy Filing1 Dec 2025 - Q3 FY2025 revenue up 8% to $408.2M; SelectRx and Life growth offset Senior declines.SLQT
Q3 202526 Nov 2025